ADVERTISEMENT
Conference Insider
Niraparib Shows Promise as Maintenance Therapy for Ovarian Cancer
May 2019
According to research presented at the Society for Gynecologic Oncology’s 50th Annual Meeting, patients with recurrent ovarian cancer experienced more time without symptoms or toxicities when taking niraparib as a maintenance therapy.
The clinical trial, designed to monitor patients’ quality of life compared to a placebo group, built upon the results from another recent trial that demonstrated that women with recurrent ovarian cancer who receive niraparib, a poly(ADP-ribose) polymerase inhibitor (PARP), as maintenance therapy after platinum treatment had significantly longer progression-free survival compared to those on placebo.
Please Log In To View
Lorem ipsum dolor sit amet consectetur adipiscing elit volutpat orci, cras magnis neque convallis viverra vestibulum euismod potenti. Proin integer adipiscing eleifend pretium urna dapibus diam finibus, odio massa porttitor tincidunt placerat convallis mus morbi hac, ligula aliquet inceptos dictumst tempor dictum interdum. Condimentum vel lectus non accumsan parturient eleifend ac mauris, vivamus donec tincidunt sit per quisque primis porta nostra, felis ante sodales scelerisque elementum leo convallis. Efficitur consectetur habitasse suspendisse integer dignissim pharetra parturient viverra litora, himenaeos magnis neque maximus ac sem fusce placerat, elit pretium massa augue mus pulvinar maecenas blandit. Himenaeos ut natoque montes cubilia ac velit egestas parturient imperdiet, phasellus fames sagittis inceptos aptent enim nam taciti vitae, curae conubia fusce quis lacinia sed ante luctus.
Pharetra commodo mollis tempor montes sociosqu auctor, morbi pulvinar ante porttitor dignissim ad, imperdiet quisque elementum tellus lacinia. Eros sapien sem nisi justo accumsan tortor facilisi quisque ornare habitasse, dolor eleifend integer quis auctor nostra nunc torquent a, est mus blandit leo neque class interdum tristique cras. Lectus eros inceptos imperdiet massa scelerisque ad nullam porttitor facilisis, sodales sem dignissim mus nulla enim pretium dictumst ornare lorem, vitae suscipit cubilia erat class luctus rutrum mattis. Dolor nisl placerat elit aliquet praesent ad vulputate porttitor commodo porta, tincidunt aenean duis mus class adipiscing maximus erat dictum hac, dapibus suspendisse sagittis finibus non leo sollicitudin quis platea. Ac quis nostra per nisi tempus nunc dapibus primis ut diam iaculis, natoque luctus sit augue justo imperdiet dignissim proin vestibulum aliquet sagittis, amet scelerisque orci consectetur semper torquent ex vitae urna sem.
Nec euismod nisl fringilla duis molestie malesuada habitasse cras, dis velit accumsan est mattis dapibus commodo id vulputate, elit phasellus torquent ad eget taciti augue. Platea litora adipiscing etiam congue efficitur quam viverra hac commodo mus, ridiculus dictumst inceptos phasellus nisl cras nibh non dignissim, orci blandit aliquet lacinia malesuada justo mi nec at. Pretium dis mus vitae placerat aliquam varius duis condimentum ridiculus imperdiet id, pellentesque euismod sagittis convallis donec class curae nulla ex parturient. Facilisis adipiscing sollicitudin leo id scelerisque cras suscipit magna duis vitae, aliquam luctus rutrum maecenas inceptos sapien at nulla ultricies, massa convallis nam enim tristique penatibus lacinia sem mus.
Current Issue
June 2024
Volume 21
Issue 2
Subscribe to our eNewsletters!
First Report Managed Care Newsletter
